Oracle to release new platform to support clinical research treatment of COVID-19
Oracle has confirmed that they will provide a platform to support clinical trials exploring if two malaria drugs could potentially be approved for the treatment of COVID-19.
Oracle will provide a new platform that will allow the US government to operate clinical trials to tackle the current global pandemic. The full details of the Oracle platform are still being finalised but it is believed the platform will allow the Department of Health and Human Services, Food and Drug Administration and Centre for Media to measure treatment scenarios with the malaria drugs.
There has been some support for the use of chloroquine and hydroxychloroquine against the current pandemic but clearly more testing is required. The platform proposed by Oracle would be capable of tracking treatments, gathering data from the field and other relevant store details associated with patients’ symptoms. The data will be essential in understanding the effectiveness of malaria drugs.